Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
9,51 USD | -0,83 % |
|
-5,94 % | -20,08 % |
Resumen de negocios
Las ventas netas se distribuyen geográficamente de la siguiente manera: Japón (28,8%), América (34,5%) y otros (36,7%).
Número de empleados: 14 484
Ventas por actividad
JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 1 296 163 | 100,0 % | 1 518 619 | 100,0 % | +17,16 % |
Ventas por región
JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 537 452 | 41,5 % | 652 441 | 43,0 % | +21,40 % |
Established Markets
23,6
%
| 315 162 | 24,3 % | 358 407 | 23,6 % | +13,72 % |
Japan
17,3
%
| 258 758 | 20,0 % | 262 303 | 17,3 % | +1,37 % |
International
9,5
%
| 110 081 | 8,5 % | 144 735 | 9,5 % | +31,48 % |
Greater China
5,3
%
| 66 305 | 5,1 % | 80 011 | 5,3 % | +20,67 % |
Other
1,4
%
| 8 406 | 0,6 % | 20 722 | 1,4 % | +146,51 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/04/86 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 01/11 |
Kenji Yasukawa
CHM | Chairman | 64 | 01/04/86 |
Compliance Officer | - | 01/10/22 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 65 | 01/09/06 | |
Noriyuki Uematsu
BRD | Director/Board Member | 64 | 01/06/16 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01/04/83 |
Atsushi Kamide
IRO | Public Communications Contact | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 01/06/21 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 01/06/17 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/04/86 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 01/06/19 |
Noriyuki Uematsu
BRD | Director/Board Member | 64 | 01/06/16 |
Eriko Sakurai
BRD | Director/Board Member | 63 | - |
Director/Board Member | 65 | 01/09/06 | |
Haruko Shibumura
BRD | Director/Board Member | 59 | 01/06/19 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01/04/83 |
Hiroo Sasaki
BRD | Director/Board Member | 68 | 01/06/18 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 1 809 663 075 | 1 788 620 803 ( 98,84 %) | 16 561 677 ( 0,9152 %) | 98,84 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
7 266 342 | 3.89% | 24 923 553 $ | |
8 333 333 | 8.59% | 24 916 666 $ | |
ASTELLAS PHARMA INC. 0.04% | 731 000 | 0.04% | 7 203 245 $ |
FIBROGEN, INC. 4.99% | 4 968 367 | 4.99% | 5 962 040 $ |
ONCOLYS BIOPHARMA INC. 3.47% | 727 200 | 3.47% | 3 040 314 $ |
Información de la empresa
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho Chuo-Ku
103-8411, Tokyo
+81 3 3244 3000
http://www.astellas.com![Dirección Astellas Pharma Inc.(ALPMY)](https://cdn.zonebourse.com/static/address/120791908.png)
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Astellas BV
![]() Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. |
Financial Conglomerates
|
Ventas por región
![Consenso](/images/consensus_flch.gif)
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+41,96 % | 630 mil M | |
-7,15 % | 350 mil M | |
+18,77 % | 328 mil M | |
+8,79 % | 298 mil M | |
+18,02 % | 246 mil M | |
+1,27 % | 225 mil M | |
+11,95 % | 218 mil M | |
+3,68 % | 160 mil M | |
-4,38 % | 156 mil M |
- Bolsa de valores
- Acciones
- Acción 4503
- Acción ALPMY
- Empresa Astellas Pharma Inc.